Skip to content

EPS (Basic) at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
$0.69+35.3%
Boston Scientific logo
Boston ScientificBSX
$0.90+95.7%
Altimmune logo
AltimmuneALT
-$0.18+30.8%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$0.47-26.6%
Wave Life Sciences logo
Wave Life SciencesWVE
-$0.13+55.2%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$13.43-4,377%

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's EPS (basic)?
Delcath Systems (DCTH) reported EPS (basic) of -$0.03 in Q1 2026.
How has Delcath Systems's EPS (basic) changed year-over-year?
Delcath Systems's EPS (basic) decreased by 200.0% year-over-year, from $0.03 to -$0.03.
What is the long-term trend for Delcath Systems's EPS (basic)?
Over 3 years (2021 to 2024), Delcath Systems's EPS (basic) has grown at a -35.6% compound annual growth rate (CAGR), from -$3.60 to -$0.96.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.